DIAGNOS to expedite application for Medical Device License to Health Canada and US FDA related to its 4 new analysis modules, and is planning ISO 27001 certification

BROSSARD, Quebec, April 16, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Company”) (TSX Venture: ADK) (OTCQB: DGNOF), a provider of healthcare services in early detection of certain critical health issues, announces today that it is working on getting new Health Canada and FDA approval on 4 additional AI analysis modules for commercialisation during Q3 2024.

Read more at globenewswire.com